Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
Children and adolescents with obsessive compulsive disorder were studied in an 8-week, multicenter, double-blind, parallel groups trial of clomipramine hydrochloride (CMI) versus placebo. Efficacy assessments included the child version of the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global rating scale. At the end of 8 weeks, CMI-treated patients showed a mean reduction in Yale-Brown Obsessive Compulsive Scale score of 37% compared to 8% in the placebo group. Side effects were typical of tricyclic antidepressants. In a 1-year open label treatment, CMI continued to be effective and well tolerated.
DeVeaugh-Geiss
J
J
Glaxo Inc., Research Triangle Park, North Carolina 27709.
Moroz
G
G
Biederman
J
J
Cantwell
D
D
Fontaine
R
R
Greist
J H
JH
Reichler
R
R
Katz
R
R
Landau
P
P
D000293:Adolescent; D002648:Child; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010552:Personality Assessment
D002997:Clomipramine